Antares Pharma Receives Payment from Teva for Commercial Development of Vibex™ Auto-Injector Product

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has received a payment from Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), which will be applied to the design and purchase of commercial tooling and assembly equipment related to an undisclosed, fixed, single-dose, disposable injector product using Antares’ Vibex™ Autoinjector platform. The payment of approximately $4 million is related to an amendment to the original License, Development and Supply Agreement signed in July 2006 between the two companies. Pursuant to the amendment, the payment mostly relates to reimbursement for commercial tooling previously paid for by Antares and an advance for the purchase of new tooling and automation equipment. The balance of the payment is an advance relating to design and development work associated with the purchased equipment. Teva will own the dedicated commercial tooling and assembly equipment, and Antares will continue to receive potential future royalty payments on Teva’s net sales of the undisclosed product as well as revenues for each device sold.

“Following the recent FDA approval of the Tev-Tropin® Tjet Injector system (needle-free hGH), we are pleased to have Teva’s financial and commercial commitment for our second injector product, which uses our proprietary Vibex platform. It is also a testimony to the focused and dedicated efforts of the management team here at Antares,” said Dr. Paul K. Wotton, Ph.D., President and Chief Executive Officer. “We look forward to making continued progress as we execute our strategic plan to build a stable, growing business while increasing shareholder value,” concluded Dr. Wotton.

About Antares Pharma

Antares Pharma is a product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has multiple development partnerships with leading pharmaceutical companies. The Company’s products are designed to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares has three validated drug delivery systems: the ATDTM Advanced Transdermal Gel Delivery system; subcutaneous injection technology platforms, including VibexTM disposable pressure-assisted auto injectors, ValeoTM/Vision® reusable needle-free injectors, and disposable multi-use pen injectors; and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA-approved products. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

Antares' Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements related to the potential device sales and royalties, the Company’s strategic plan of building a stable growing business, and other statements which are other than statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.